November 17, 2014

Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock, the company announced Monday.

October 23, 2014

Actavis on Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid.

October 7, 2014

Actavis and Durata Therapeutics on Monday announced that they have entered into a definitive merger agreement.

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

July 3, 2014

Impax Labs on Wednesday announced that it has acquired from Actavis two generic products for cash consideration. Financial terms of the agreement were not disclosed.

July 2, 2014

Actavis on Wednesday announced that its subsidiary Forest Labs has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug, following approval.

July 1, 2014

Actavis and Forest Labs. on Monday announced that the U.S. Federal Trade Commission has voted to approve Actavis' proposed acquisition of Forest.

June 30, 2014

Actavis on Monday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablets.

June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

June 17, 2014

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

June 3, 2014

Actavis last week announced that it has reached an agreement with Cephalon to settle all outstanding patent litigation associated with Actavis' generic version of Nuvigil (armodafinil tablets).

May 29, 2014

Gov. Alejandro García Padilla on Wednesday announced an agreement by Puerto Rico Industrial Development Co. with Actavis that will allow the pharmaceutical manufacturer to develop a solid dosage manufacturing and packing facility in its Manati site and expand its current hormone production in Fajardo.

May 28, 2014

Actavis on Tuesday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg.

May 15, 2014

Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.

May 14, 2014

Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).

May 14, 2014

Actavis on Wednesday announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Labs, which is anticipated at mid-year.

May 13, 2014

Valeant Pharmaceuticals on Monday announced that certain of its subsidiaries have entered into settlement agreements with Actavis related to Actavis' generic versions of Tiazac XC.

May 12, 2014

Actavis on Monday announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.

May 8, 2014

Actavis announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS (clonidine transdermal system, USP, 0.1-mg/day, 0.2-mg/day, and 0.3-mg/day for one week).

April 24, 2014

A cough syrup produced by Actavis will no longer be available due to the negative light cast on the product stemming from abuse by musicians like Justin Bieber and Soulja Boy, according to a report from the Huffington Post.

April 22, 2014

Impax Labs on Monday announced the its board of directors appointed G. Frederick Wilson as the company's president and CEO, effective April 29.

April 21, 2014

By adding complementary specialty medication offerings to their generic drug businesses, manufacturers can add instant value and counteract the margin compression that is currently occurring as a result of high generic drug utilization.

April 18, 2014

Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.

April 18, 2014

Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.